June 2, 2011

Press release

Mitsubishi Tanabe Pharma Corporation

AZANIN® Tablets 50mg, Immunosuppressant
Approval for Additional Indication for Refractory Rheumatic Diseases

Osaka, Japan, June 2, 2011---Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) announced today that the Company obtained approval, as of May 20, 2011, for additional indications for AZANIN® Tablets 50mg, immunosuppressant (generic name: JP Azathioprine Tablets) for refractory rheumatic diseases such as systemic vasculitis (microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, scleroderma, mixed connective-tissue disease, and intractable rheumatic diseases.

Since 1978, AZANIN® has been widely used for over 30 years in a medical practice for the indications of prevention of rejection in kidney transplant, liver transplant, heart transplant and lung transplant, and achieving and maintaining remission of steroid dependent Crohn's disease as well as maintaining remission of steroid dependent ulcerative colitis.

In Japan, as part of an initiative by the Ministry of Health, Labor and Welfare to eliminate drug lag, the Second Committee on Pharmaceutical Products of the Pharmaceutical Affairs and Food Sanitation Council issued a pre-assessment report in October 2010 that an “application for approval of additional indication for a publicly known prescription” may be filed for additional indications of systemic vasculitis and SLE as well as other auto immune diseases. Based on this pre-assessment report, the Company filed an application for approval of additional indications for a publicly known prescription in November, 2010, and the approval was obtained for these additional indications.

Mitsubishi Tanabe Pharma will strive to contribute to the treatment of as many patients as possible and improve their QOL by continuing research & development, and stable supply of pharmaceuticals that meet unmet medical needs.

<Contact for Inquiries>
Corporate Communications Department
Phone: +81 6-6205-5211